On March 30, 2026, Increase Innovative Medicine officially announced that its independently developed Class 1.1 traditional Chinese medicine innovative drug, "Kidney-Tonifying and Fluid-Conserving Granules," has received clinical trial approval from the Center for Drug Evaluation of the National Medical Products Administration (NMPA) for the treatment of stress urinary incontinence.

Notably, Jiangxi Zvast-Biotechnology Co., Ltd., as the core service provider for the preclinical efficacy research of this drug, leveraged its high-standard technical services and extensive experience in IND (Investigational New Drug) application to help "Kidney-Tonifying and Fluid-Conserving Granules" successfully pass the preclinical review and obtain clinical trial approval from the CDE (Center for Drug Evaluation). This laid a solid foundation for its efficient clinical translation and demonstrated Zvast-Bio's strong capabilities in the field of preclinical efficacy research.

Increase Innovative Medicine's Traditional Chinese Medicine continues to make strides in innovative drug development, filling market gaps.

The newly approved "Kidney-Tonifying and Fluid-Conserving Granules" are derived from a clinically experienced formula, modified from Wuzi Yanzong Wan and Buzhong Yiqi Tang, and have shown significant efficacy in clinical application for many years. Indications: Tonifies Qi and kidneys, consolidates and astringes urine. Used for stress urinary incontinence due to kidney deficiency and instability, characterized by involuntary urine leakage after coughing, sneezing, crying, laughing, lifting heavy objects, etc., accompanied by cold limbs, lower back and knee weakness, bedwetting, frequent and clear urination, incomplete urination, fecal incontinence, tinnitus, pale tongue, white coating, and weak pulse.

Currently, there are no traditional Chinese medicines (TCM) approved for the treatment of stress urinary incontinence (SUI). Statistics show that at least 21.6% of the global population suffers from urinary incontinence. The global market size for urinary incontinence medications is estimated at US$4.68-4.7 billion in 2025, with a CAGR of 4.5%-6.9% (2025-2032). The overall market size for urinary incontinence medications in China is estimated at RMB 35-40 billion in 2025, with a market penetration rate of approximately 28.7% for adult incontinence products, far lower than the 60%+ in developed countries, indicating significant room for growth. The development and launch of this product will fill a market gap, not only providing clinical practice with an effective innovative TCM drug, reflecting the profound significance of the modern application of TCM, but also possessing outstanding market potential and significant social benefits.

Zvast-Bio technological empowerment demonstrates its strong capabilities in preclinical research.

As a key partner of Yingkerui, Zvast-Bio undertook the preclinical pharmacodynamic research of "Kidney-Tonifying and Fluid-Conserving Granules". Relying on a high-standard animal model construction platform, it provided comprehensive preclinical pharmacodynamics and supporting functional pharmacodynamic analysis services for the drug, accurately controlling every aspect of the preclinical research, ensuring the scientific, compliant and reliable nature of the research data, and escorting the drug to enter clinical trials smoothly.

Founded in 2015, Zvast-Bio is a high-tech enterprise specializing in the research and development of animal models for human diseases. The company has built SPF-grade animal facilities that meet international AAALAC standards—AAALAC certification is an internationally recognized symbol of laboratory animal quality and biosafety standards, ensuring international standardization in experimental research. Simultaneously, it has constructed a comprehensive standardized laboratory animal quality control system and a high-standard intelligent laboratory, providing solid hardware support for preclinical drug research.

Professional support helps Zvast-Bio accelerate the IND application process for innovative drugs.

The successful approval of the clinical trial for "Kidney-Tonifying and Fluid-Conserving Granules" is not only a significant achievement for Increase Innovative Medicine, which has consistently adhered to its core strategy of inheriting, innovating, and industrializing traditional Chinese medicine, and has been deeply involved in the development of innovative Chinese medicine drugs and new formulations, but also a vivid demonstration of Zvast-Bio's preclinical technical service capabilities. As a high-tech enterprise deeply involved in the research and development of animal models for human diseases and preclinical evaluation, Zvast-Bio has accumulated data for more than 20 IND applications. With its core technological advantages, high-standard service system, and rich project experience, it has become an important contributor to the innovative drug development process.

Looking ahead, Zvast-Bio will remain committed to its professional mission, leveraging its proprietary core technologies and high-standard service platform to continuously enhance its preclinical research service capabilities. It will deepen cooperation with innovative pharmaceutical companies both domestically and internationally, focusing on unmet clinical needs and providing higher-quality, more efficient one-stop preclinical technical services to help more innovative drugs accelerate clinical translation and achieve global reach. Simultaneously, it will continue to deepen its expertise in the development of animal models for human diseases, strengthening technological innovation and talent cultivation to improve the quality and efficiency of domestic innovative drug development, contributing to the high-quality upgrading of my country's pharmaceutical industry and providing better treatment options for patients worldwide.